A Breakthrough Discovery for the Immune System.
|
|
|
|
|
|
|
SanRx Pharmaceuticals has developed two breakthrough immune-boosting compounds based on the naturally occurring human small molecule "pterin," the same compound that gives butterfly wings their pigment.
In early testing by reputable third-party laboratories, the pterin-based compounds discovered by SanRx (Pterin+Calcium and DCP) suggest a strong ability to boost the human immune system against a number of disease conditions, including:
|
|
|
Without the harmful side effects or cost of traditional therapies.
|
|
|
|
Progress
In recent months, SanRx has made significant
progress in the following areas:
 Cancerous Tumors
We are currently preparing an application to the
Department of Defense's Congressionally Directed
Medical Research Program in Breast Cancer for
clinical trials with calcium pterins.
Hepatitis B
We are in contact with the NIH/NIAID (National
Institute of Allergies and Infectious Diseases)
regarding possible avenues for further development
of DCP as a Hepatitis B therapeutic.
Tuberculosis
In collaboration with Drs. Daniel Hoft and Isaac
Sakala at St. Louis University (SLU is ranked
among the top research institutions in the nation),
research findings have demonstrated efficacy
for DCP in an in vitro tuberculosis model. TB is
one of the third-world diseases targeted by The
Gates Foundation. SanRx is in the process of
preparing the SLU research results to present to
the Foundation, with the aim of pursuing clinical
studies.
Diabetes
In collaboration with the Millipore Corporation (a
life science leader in bioscience research), diabetes
samples from a recent diet-induced obesity (DIO)
mouse study have been analyzed. Dr. Dietmar Fuchs
at the Innsbruck Medical University, Austria, will
be further analyzing the samples for indoleamine
2,3-dioxygenase (IDO) metabolites. A manuscript
based on the positive results is being prepared for
publication, as well as a Small Business Innovation
Program (SBIR) proposal to the NIDDK, the
Diabetes Institute of the National Institutes of Health
(NIH).
|
Bio - Phillip Moheno, PhD
In addition to more than 20 years of research experience into the anticancer properties of pterins, acting SanRx
president and chief scientist Dr. Moheno has seven years of experience in intellectual property and partnerships and acted as Chief Executive Officer and Principal Investigator for San Diego Research.
Dr. Moheno's research and development activities in cancer pharmacology have led
to the awarding of three US patents with another application in process.
Read More »
Want to learn more
about SanRx?
Download a brief SanRx Pharamceuticals presentation.
View the SanRx report
submitted to the National
Institute of Health in June 2011.
FDA Update
The FDA is requiring a long term (90 day) rat toxicological study for approval of Pterin+Calcium as a nutritional
supplement.
We are in the process of raising money for this study and welcome all contributions.
|
|
|
|
We welcome your interest and contribution!
Would you, or a colleague of yours, be interested in contributing to the development of these breakthrough discoveries?
Let us know by downloading the investment summary and providing your contact information.
|
|
